Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

Validating an Integrated Biomarker and Imaging Approach in the Evaluation of Indeterminate Pulmonary Nodules.

Lung

Lung
N/A
Grogan, Eric
VICCTHO2002

Liquid Biopsy of The Lung to Profile Lung Cancer

Lung

Lung
N/A
Maldonado, Fabien
VICCTHO2107

Developing a Trustworthy Multilevel Intervention to Improve Equity in Lung Cancer Screening

Lung

Lung
N/A
Richmond, Jennifer
VICC-VDTHO23221

Impact of Indwelling Tunneled Pleural Drainage Systems (Gravity or Vacuum Based) on Pain in Patients with Recurrent Pleural Effusions

Lung

This trial studies the impact of indwelling tunneled pleural drainage systems (gravity or vacuum based) on pain in patients with plural effusion that has come back (recurrent). Vacuum drainage and gravity drainage are two commonly used drainage methods. Studying the best drainage methods may help future patients undergoing indwelling tunneled pleural catheter placement.
Lung
N/A
Maldonado, Fabien
NCT03831386
VICCTHO19118

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules - A Multicenter Prospective Observational Pilot Study

Lung

This study is being done to evaluate a combined biomarker model for risk stratification of indeterminate pulmonary nodules.
Lung
N/A
Grogan, Eric
NCT06074133
VICC-EDTHO23230

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial

Lung

This phase III trial compares the effect of the combination therapy with ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if combination therapy with ramucirumab and pembrolizumab could help patients with stage IV or recurrent non-small cell lung cancer live longer compared to standard chemotherapy.
Lung
III
Iams, Wade
NCT05633602
VICC-NTTHO23073

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.